

## ASX Release

### **Anatara closes heavily subscribed Share Purchase Plan (SPP)**

#### **Key points:**

- **SPP heavily subscribed in applications**
- **Strongly supported by shareholders**
- **Follows oversubscribed placement**
- **Funds to be used to further advance registration and development of Detach™**
- **Move into new markets faster**

BRISBANE, 28th July 2015: Anatara Lifesciences (ASX:ANR) is pleased to announce it has raised \$2 million through a significantly subscribed Share Purchase Plan.

The capital raising follows an announcement on the 3<sup>rd</sup> July that the Company had successfully raised \$7 million through a heavily oversubscribed placement to wholesale, sophisticated and professional investors. The second tranche component of the placement is subject to shareholder approval at a General Meeting to be held on the 10<sup>th</sup> August.

The combined funds raised will fund international registration and further development of its lead therapy, Detach™, a non-antibiotic, natural therapy to treat and prevent diarrhoea in pigs and other livestock animals.

Anatara's Share Purchase Plan offered each eligible shareholder the opportunity to subscribe for up to \$15,000 in Anatara shares. Due to the strong response shareholders will receive approximately 60% of the allocation for which they applied. This is a similar scale back afforded under the Placement.

Anatara Chairman Dr Mel Bridges thanked shareholders for their commitment to the company and support for its strategic direction and future potential.

“The combined \$9 million raised will allow Anatara to move into both Europe and the US markets in parallel, as well as target the larger Asian markets earlier than originally forecast. We will also be investigating moving into other livestock such as poultry and calves whilst advancing development of Detach™’s use in humans,” he said.

“The fund raising puts Anatara in a secure position as we continue discussions with global partners and will allow us to rapidly roll out Detach™ globally as we receive regulatory approvals.”

As previously announced, a second field trial for Detach™ began in June, with the results expected in the third quarter of calendar 2015. Anatara expects Detach™ to be on sale in Australia within 12 months of lodging its regulatory approval application to the APVMA based on the pace of current progress.

**For more information please contact:**

**General inquiries**

Dr Paul Schober  
CEO, Anantara Lifesciences  
+61 412 026 657  
[pschober@anataralifesciences.com](mailto:pschober@anataralifesciences.com)

Dr Mel Bridges

Chairman

+61413051600

[melbridges@parmacorporation.com](mailto:melbridges@parmacorporation.com)

**Media inquiries**

Gavin Lower  
Buchan Consulting  
03 8866 1215  
[glower@buchanwe.com.au](mailto:glower@buchanwe.com.au)

**About Anantara Lifesciences**

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.